Viewing Study NCT06341660


Ignite Creation Date: 2025-12-25 @ 2:12 AM
Ignite Modification Date: 2026-02-26 @ 4:18 PM
Study NCT ID: NCT06341660
Status: RECRUITING
Last Update Posted: 2024-04-02
First Post: 2024-03-13
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: To Evaluate the Safety and Tolerability of Carbognilumab Combined With Chemotherapy as the First-line Treatment for Patients With KEAP1 Mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer (NSCLC)
Sponsor: Guangzhou Institute of Respiratory Disease
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module